AU2016219247B2 - Fused dihydro-4H-pyrazolo[5,1-C][1,4]oxazinyl compounds and analogs for treating CNS disorders - Google Patents

Fused dihydro-4H-pyrazolo[5,1-C][1,4]oxazinyl compounds and analogs for treating CNS disorders Download PDF

Info

Publication number: AU2016219247B2
Authority: AU; Australia
Prior art keywords: compound; pharmaceutically acceptable; acceptable salt; boc; formula
Prior art date: 2015-02-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

AU2016219247A

Other languages

English (en)

Other versions

AU2016219247A1 (en

Inventor

Vadim ALEXANDROV

Milan Chytil

Sharon Engel

Taleen G. Hanania

Emer Leahy

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

PGI Drug Discovery LLC

Sumitomo Pharma America Inc

Original Assignee

Sunovion Pharmaceuticals Inc

PGI Drug Discovery LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-02-11

Filing date

2016-02-11

Publication date

2020-08-13

2016-02-11 Application filed by Sunovion Pharmaceuticals Inc, PGI Drug Discovery LLC filed Critical Sunovion Pharmaceuticals Inc

2017-09-21 Publication of AU2016219247A1 publication Critical patent/AU2016219247A1/en

2020-08-13 Application granted granted Critical

2020-08-13 Publication of AU2016219247B2 publication Critical patent/AU2016219247B2/en

2020-11-11 Priority to AU2020267209A priority Critical patent/AU2020267209A1/en

2022-10-28 Priority to AU2022259828A priority patent/AU2022259828A1/en

2024-06-24 Priority to AU2024204310A priority patent/AU2024204310A1/en

Status Expired - Fee Related legal-status Critical Current

2036-02-11 Anticipated expiration legal-status Critical

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Diabetes (AREA)
Hematology (AREA)
Psychology (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Physical Education & Sports Medicine (AREA)
Otolaryngology (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AU2016219247A 2015-02-11 2016-02-11 Fused dihydro-4H-pyrazolo[5,1-C][1,4]oxazinyl compounds and analogs for treating CNS disorders Expired - Fee Related AU2016219247B2 (en)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
AU2020267209A AU2020267209A1 (en)	2015-02-11	2020-11-11	Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
AU2022259828A AU2022259828A1 (en)	2015-02-11	2022-10-28	Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
AU2024204310A AU2024204310A1 (en)	2015-02-11	2024-06-24	Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562115043P	2015-02-11	2015-02-11
US62/115,043		2015-02-11
PCT/US2016/017527 WO2016130790A1 (en)	2015-02-11	2016-02-11	Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2020267209A Division AU2020267209A1 (en)	2015-02-11	2020-11-11	Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders

Publications (2)

Publication Number	Publication Date
AU2016219247A1 AU2016219247A1 (en)	2017-09-21
AU2016219247B2 true AU2016219247B2 (en)	2020-08-13

Family

ID=55456906

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
AU2016219247A Expired - Fee Related AU2016219247B2 (en)	2015-02-11	2016-02-11	Fused dihydro-4H-pyrazolo[5,1-C][1,4]oxazinyl compounds and analogs for treating CNS disorders
AU2020267209A Abandoned AU2020267209A1 (en)	2015-02-11	2020-11-11	Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
AU2022259828A Abandoned AU2022259828A1 (en)	2015-02-11	2022-10-28	Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
AU2024204310A Abandoned AU2024204310A1 (en)	2015-02-11	2024-06-24	Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
AU2020267209A Abandoned AU2020267209A1 (en)	2015-02-11	2020-11-11	Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
AU2022259828A Abandoned AU2022259828A1 (en)	2015-02-11	2022-10-28	Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
AU2024204310A Abandoned AU2024204310A1 (en)	2015-02-11	2024-06-24	Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders

Country Status (21)

Country	Link
US (4)	US9758529B2 (2)
EP (3)	EP3256476B1 (2)
JP (4)	JP6561128B2 (2)
KR (1)	KR102623321B1 (2)
CN (2)	CN111171047B (2)
AU (4)	AU2016219247B2 (2)
BR (1)	BR112017017349B1 (2)
CA (1)	CA2976092A1 (2)
DK (1)	DK3256476T3 (2)
EA (1)	EA201791802A1 (2)
ES (1)	ES2712627T3 (2)
IL (2)	IL253907B (2)
MX (1)	MX371197B (2)
NZ (1)	NZ734972A (2)
PH (1)	PH12017501423A1 (2)
PL (1)	PL3256476T3 (2)
PT (1)	PT3256476T (2)
SG (1)	SG11201706516WA (2)
UA (1)	UA123262C2 (2)
WO (1)	WO2016130790A1 (2)
ZA (1)	ZA201706074B (2)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102623321B1 (ko) *	2015-02-11	2024-01-09	선오비온 파마슈티컬스 인코포레이티드	중추 신경계 질환을 치료하기 위한 융합된 다이하이드로-4h-피라졸로[5,1-c][1,4]옥사진일 화합물 및 유사체
MA45795A (fr)	2016-07-29	2019-06-05	Sunovion Pharmaceuticals Inc	Composés et compositions, et utilisations associées
PT3494119T (pt)	2016-07-29	2024-12-10	Pgi Drug Discovery Llc	Compostos e composições e seus usos
KR101753092B1 (ko)	2016-12-14	2017-07-04	성일하이텍(주)	리튬 함유 폐액으로부터 인산리튬 제조방법
US10850989B2 (en)	2016-12-20	2020-12-01	Sungeel Hitech Co., Ltd.	Method for preparing solid lithium salt from lithium solution
CA3104811C (en)	2017-06-30	2024-05-28	Chase Therapeutics Corporation	Composition comprising pramipexole and nk1-antagonists for treating depression
CA3070993C (en)	2017-08-02	2025-05-20	Sunovion Pharmaceuticals Inc.	ISOCHROMANE COMPOUNDS AND THEIR USES
WO2019236808A1 (en)	2018-06-07	2019-12-12	Sunovion Pharmaceuticals Inc.	Salts of a oxazino[4,3-b]indazole derivative and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
US20210393621A1 (en)	2018-10-26	2021-12-23	The Research Foundation For The State University Of New York	Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
EP3938045A1 (en)	2019-03-14	2022-01-19	Sunovion Pharmaceuticals Inc.	Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
TW202237622A (zh) *	2020-12-04	2022-10-01	美商蘇諾維恩藥業公司	雜環化合物的鹽及其晶型、製備方法、治療用途與醫藥組合物
WO2022217233A1 (en) *	2021-04-08	2022-10-13	Sunovion Pharmaceuticals Inc.	Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
EP4416133A1 (en) *	2021-10-11	2024-08-21	Baylor College of Medicine	G-protein-coupled receptor regulators and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013067248A1 (en) *	2011-11-04	2013-05-10	Vertex Pharmaceuticals Incorporated	Benzoxazines as modulators of ion channels

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3995052A (en) *	1973-07-09	1976-11-30	Ayerst Mckenna And Harrison Ltd.	Indenopyran- and indenothiopyranalkylamines III in the treatment of depression
US4041169A (en) *	1975-03-05	1977-08-09	Ayerst Mckenna And Harrison Ltd.	Pharmaceutical method for using pyrano-and thiopyranoindole derivatives
MX2008013053A (es) *	2006-04-12	2008-10-17	Wyeth Corp	Derivados de dihidri[1,4]oxazino[2,3,4-hi]indazol-sustituidos como ligandos de 5-hidroxitriptamina-6.
BRPI1008020A2 (pt) *	2009-02-11	2016-03-15	Sunovion Pharmaceuticals Inc	antagonistas e agonistas inversos h3 da histamina e métodos de uso dos mesmos
SG10201510665WA (en) *	2009-12-04	2016-01-28	Sunovion Pharmaceuticals Inc	Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders
TW201500358A (zh) *	2010-12-16	2015-01-01	赫夫門羅氏藥廠股份有限公司	三環ｐｉ３ｋ抑制劑化合物及其使用方法
KR20140082765A (ko) *	2011-10-05	2014-07-02	에프. 호프만-라 로슈 아게	V1a 길항제로서의 사이클로헥실-4H,6H-5-옥사-2,3,10b-트라이아자-벤조[e]아줄렌
AU2012357169B2 (en) *	2011-12-22	2017-03-30	Merck Patent Gmbh	Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
MX2014014911A (es) *	2012-06-20	2015-05-15	Univ Vanderbilt	Análogos de alcoxi pirazol bicíclico sustituido como moduladores alostéricos de receptores de mglur5.
JP2014214130A (ja) *	2013-04-26	2014-11-17	大正製薬株式会社	ジヒドロイミダゾオキサゾール誘導体を含有する医薬
KR102601972B1 (ko) *	2015-02-11	2023-11-13	선오비온 파마슈티컬스 인코포레이티드	중추 신경계 질환을 치료하기 위한 1-헤테로사이클릴 이소크로만일 화합물 및 유사체
KR102623321B1 (ko) *	2015-02-11	2024-01-09	선오비온 파마슈티컬스 인코포레이티드	중추 신경계 질환을 치료하기 위한 융합된 다이하이드로-4h-피라졸로[5,1-c][1,4]옥사진일 화합물 및 유사체

2016
- 2016-02-11 KR KR1020177025289A patent/KR102623321B1/ko active Active
- 2016-02-11 DK DK16708260.1T patent/DK3256476T3/en active
- 2016-02-11 JP JP2017542400A patent/JP6561128B2/ja not_active Expired - Fee Related
- 2016-02-11 MX MX2017010362A patent/MX371197B/es active IP Right Grant
- 2016-02-11 EP EP16708260.1A patent/EP3256476B1/en active Active
- 2016-02-11 EP EP21198192.3A patent/EP4006039B1/en active Active
- 2016-02-11 UA UAA201708954A patent/UA123262C2/uk unknown
- 2016-02-11 WO PCT/US2016/017527 patent/WO2016130790A1/en not_active Ceased
- 2016-02-11 EP EP18213435.3A patent/EP3539967A1/en not_active Withdrawn
- 2016-02-11 EA EA201791802A patent/EA201791802A1/ru unknown
- 2016-02-11 BR BR112017017349-2A patent/BR112017017349B1/pt not_active IP Right Cessation
- 2016-02-11 NZ NZ734972A patent/NZ734972A/en not_active IP Right Cessation
- 2016-02-11 PL PL16708260T patent/PL3256476T3/pl unknown
- 2016-02-11 PT PT16708260T patent/PT3256476T/pt unknown
- 2016-02-11 ES ES16708260T patent/ES2712627T3/es active Active
- 2016-02-11 SG SG11201706516WA patent/SG11201706516WA/en unknown
- 2016-02-11 AU AU2016219247A patent/AU2016219247B2/en not_active Expired - Fee Related
- 2016-02-11 US US15/041,827 patent/US9758529B2/en not_active Expired - Fee Related
- 2016-02-11 CA CA2976092A patent/CA2976092A1/en active Pending
- 2016-02-11 CN CN202010051639.8A patent/CN111171047B/zh not_active Expired - Fee Related
- 2016-02-11 CN CN201680018684.5A patent/CN107567454B/zh not_active Expired - Fee Related
2017
- 2017-08-02 US US15/666,719 patent/US20180057506A1/en not_active Abandoned
- 2017-08-08 IL IL253907A patent/IL253907B/en active IP Right Grant
- 2017-08-09 PH PH12017501423A patent/PH12017501423A1/en unknown
- 2017-09-06 ZA ZA2017/06074A patent/ZA201706074B/en unknown
2019
- 2019-05-06 US US16/403,734 patent/US20200024286A1/en not_active Abandoned
- 2019-07-22 JP JP2019134260A patent/JP6928629B2/ja not_active Expired - Fee Related
2020
- 2020-09-29 IL IL277658A patent/IL277658B/en unknown
- 2020-11-11 AU AU2020267209A patent/AU2020267209A1/en not_active Abandoned
2021
- 2021-02-19 US US17/179,477 patent/US20210300942A1/en not_active Abandoned
- 2021-08-06 JP JP2021129696A patent/JP2021183624A/ja not_active Ceased
2022
- 2022-10-28 AU AU2022259828A patent/AU2022259828A1/en not_active Abandoned
- 2022-12-02 JP JP2022193341A patent/JP2023036611A/ja not_active Ceased
2024
- 2024-06-24 AU AU2024204310A patent/AU2024204310A1/en not_active Abandoned

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013067248A1 (en) *	2011-11-04	2013-05-10	Vertex Pharmaceuticals Incorporated	Benzoxazines as modulators of ion channels

Also Published As

Publication number	Publication date
PH12017501423A1 (en)	2018-03-19
AU2024204310A1 (en)	2024-07-11
US20160264597A1 (en)	2016-09-15
BR112017017349B1 (pt)	2024-01-23
SG11201706516WA (en)	2017-09-28
WO2016130790A1 (en)	2016-08-18
CN107567454B (zh)	2020-02-18
JP2019196385A (ja)	2019-11-14
EP4006039B1 (en)	2024-01-10
IL277658A (en)	2020-11-30
IL277658B (en)	2022-03-01
JP2023036611A (ja)	2023-03-14
PT3256476T (pt)	2019-03-01
CN111171047A (zh)	2020-05-19
AU2016219247A1 (en)	2017-09-21
EP3539967A1 (en)	2019-09-18
CN107567454A (zh)	2018-01-09
AU2020267209A1 (en)	2020-12-10
BR112017017349A2 (en)	2018-04-10
NZ734972A (en)	2023-07-28
US9758529B2 (en)	2017-09-12
ES2712627T3 (es)	2019-05-14
JP2018505204A (ja)	2018-02-22
US20180057506A1 (en)	2018-03-01
IL253907B (en)	2020-09-30
IL253907A0 (en)	2017-10-31
US20210300942A1 (en)	2021-09-30
KR102623321B1 (ko)	2024-01-09
KR20170129729A (ko)	2017-11-27
JP2021183624A (ja)	2021-12-02
US20200024286A1 (en)	2020-01-23
UA123262C2 (uk)	2021-03-10
PL3256476T3 (pl)	2019-05-31
CN111171047B (zh)	2023-06-23
JP6928629B2 (ja)	2021-09-01
ZA201706074B (en)	2023-05-31
MX2017010362A (es)	2018-05-04
DK3256476T3 (en)	2019-03-11
CA2976092A1 (en)	2016-08-18
MX371197B (es)	2020-01-22
JP6561128B2 (ja)	2019-08-14
EP4006039A1 (en)	2022-06-01
EP3256476B1 (en)	2019-01-23
AU2022259828A1 (en)	2022-12-01
EP3256476A1 (en)	2017-12-20
EA201791802A1 (ru)	2018-02-28

Legal Events

Date	Code	Title	Description
2020-12-17	MK25	Application lapsed reg. 22.2i(2) - failure to pay acceptance fee

Publication	Publication Date	Title
AU2016219247B2 (en)	2020-08-13	Fused dihydro-4H-pyrazolo[5,1-C][1,4]oxazinyl compounds and analogs for treating CNS disorders
AU2016219253B2 (en)	2020-10-01	1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders
AU2018312559A1 (en)	2020-02-13	Isochroman compounds and uses thereof
HK40073618A (en)	2022-12-23	Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
HK40006461A (en)	2020-05-22	Process for the preparation of fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds
HK40073618B (en)	2024-08-30	Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
HK1241875A1 (en)	2018-06-15	Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
HK1241875B (en)	2020-03-20	Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
HK40078692B (en)	2023-11-03	1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
HK40078692A (en)	2023-04-06	1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders